| Authors: |
Watts GF; School of Medicine, University of Western Australia, Perth, Western Australia, Australia. gerald.watts@uwa.edu.au., Schwabe C; Auckland Clinical Studies, Auckland, New Zealand., Scott R; New Zealand Clinical Research Christchurch, Christchurch, New Zealand., Gladding PA; Te Whatu Ora Waitematā, Auckland, New Zealand., Sullivan D; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Baker J; Middlemore Hospital, Auckland, New Zealand., Clifton P; Royal Adelaide Hospital, Adelaide, South Australia, Australia., Hamilton J; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA., Given B; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA., Melquist S; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA., Zhou R; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA., Chang T; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA., San Martin J; Arrowhead Pharmaceuticals, Inc., Pasadena, CA, USA., Gaudet D; Department of Medicine, Université de Montréal and ECOGENE 21 Clinical Research Center, Chicoutimi, Quebec, Canada., Goldberg IJ; NYU School of Medicine, NYU Langone Health, New York City, NY, USA., Knowles JW; Stanford Division of Cardiovascular Medicine and Cardiovascular Institute, School of Medicine, Stanford, CA, USA., Hegele RA; University of Western Ontario, London, Ontario, Canada., Ballantyne CM; Baylor College of Medicine, Houston, TX, USA. |
